Date: 2016-01-19
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Galapagos (Belgium)
Product: GLPG2222
Action mechanism:
Disease: cystic fibrosis
Therapeutic area: Rare diseases - Genetic diseases
Country: Belgium
Trial details:
Latest
news: * On January 19, 2016, Galapagos has provided an update on progress made in the cystic fibrosis (CF) programs. Galapagos and AbbVie aim to develop a triple CFTR combination therapy to address 90% of patients with CF. In order to bring a more effective therapy to patients, the companies plan to develop multiple candidates and backups for each of the three components (1st generation correctors, next generation correctors, and potentiators) with the goal of identifying a potential triple combination. In addition to Galapagos' potentiator and corrector that are being tested in the clinic, a total of four additional compounds have the potential to reach clinical development in the CF program this year.
Dosing to humans of GLPG2222, the first 1st generation corrector in Galapagos' portfolio, started earlier this month. This achievement earns Galapagos a $10 million milestone payment in connection with the global collaboration agreement with AbbVie. Galapagos is conducting a randomized, double-blind, placebo-controlled study over a range of doses of GLPG2222 in healthy volunteers in Belgium and expects topline results in Q2 2016. Galapagos further announces the selection of preclinical candidate GLPG2851, an additional 1st generation corrector, aiming to initiate Phase 1 with this compound by the end of 2016.
